136779-82-3

Usage

Class

Cyclohexenes

Physical State

Colorless to light yellow liquid

Odor

Faint

Primary Use

Fragrance ingredient in cosmetic and personal care products

Skin Sensitizing Properties

Known for potential skin sensitization

Concentration

Used in low concentrations due to sensitizing properties

Research Applications

Studied for potential application in organic synthesis and pharmaceuticals

Industrial Applications

Fragrance and organic chemistry fields

Upstream product

• 712-50-5 Cyclohexyl phenyl ketone 
• 1730-25-2 allylmagnesium bromide 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 136722-14-0 1-Cyclohexyl-2-(3-dimethylamino-prop-1-ynyl)-1-phenyl-propane-1,3-diol 
• 136722-21-9 1-cyclohexyl-1-hydroxy-1-phenyl-1-(trimethylsiloxy)-2,3-oxirane 
• 136722-22-0 1-cyclohexyl-1-hydroxy-1-phenyl-2-(hydroxymethyl)-3-propyne 
• 136722-61-7 1-cyclohexyl-1-phenyl-1-(trimethylsiloxy)-2-propene 

Relevant academic research and scientific papers

Electrochemical Oxidative Aryl(alkyl)trifluoromethylation of Allyl Alcohols via 1,2-Migration

An electrochemical oxidative difunctionalization of allyl alcohols for the synthesis of β-trifluoromethyl ketones is achieved through a 1,2-migration process. A series of β-trifluoromethyl ketones can be facilely obtained utilizing CF3SO2

Analogues of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds

Oxybutynin chloride [4-(diethylamino)-2-butynyl α-cyclohexyl-α-hydroxybenzeneacetate hydrochloride, Ditropan] is widely used for the relief of symptoms in neurogenic bladder. This is a result of its combined anticholinergic, antispasmodic, and local anesthetic activities. In a study directed toward development of agents possessing the beneficial properties of oxybutynin, but having a longer duration of action, a series of metabolically more stable keto analogues of the parent ester, i.e. substituted 7-amino-1-hydroxy-5-heptyn-2-ones along with some analogues and derivatives, was prepared and evaluated for in vitro and in vivo antimuscarinic action in guinea pig preparations. Several members of the series were potent antimuscarinics having a longer duration of activity than that of oxybutynin in a guinea pig cystometrogram model. On the basis of its in vitro and in vivo antimuscarinic activity, coupled with a 5-fold greater duration of action than that of oxybutynin, 1-cyclobutyl-7-(dimethylamino)-1-hydroxy-1-phenyl-5-heptyn-2-one (14b) was selected for clinical evaluation.